Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2010-05-23 AGM Information
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Annual General Meeting 2010
AGM Information Classification · 98% confidence The document is explicitly titled 'Annual General Meeting 2010' and contains an 'Agenda' listing items typically voted on at an AGM (e.g., approval of financial statements, appointment of auditors, resolution on remuneration scheme). It also includes a 'Report of the Management Board' with operational and financial reviews for the business year 2009 and outlook for 2010. This structure—combining meeting agenda/proceedings with annual performance review—is characteristic of materials presented or distributed at an Annual General Meeting. While it contains elements of an Annual Report (financial review), the primary context and framing are centered around the meeting itself. Therefore, AGM-R (AGM Information) is the most appropriate classification over 10-K (Annual Report) or MDA (Management Reports).
2010-05-23 English
AGM Information 2010
AGM Information Classification · 100% confidence The document text is a verbatim transcript or presentation slides from a formal corporate event. Key indicators include: 1. Title: "MorphoSys AG Ordentliche Hauptversammlung am 21. Mai 2010" (MorphoSys AG Annual General Meeting on May 21, 2010). 2. Structure: It follows a typical AGM agenda (Begrüßung, Tagesordnung, Bericht des Vorstands) and features speeches from key executives (Dr. Simon E. Moroney, Dr. Marlies Sproll, Dr. Arndt Schottelius). 3. Content: The content reviews the past year's performance (2009) and provides outlooks, which is standard for an AGM presentation. 4. Definition Match: This directly matches the definition for 'AGM Information' (Code: AGM-R): 'Presentations and materials shared during the Annual General Meeting (AGM)'. 5. Length Check: The document is long (47,652 chars), confirming it is the presentation material itself, not just a brief announcement (RPA/RNS).
2010-05-21 German
Hauptversammlung 2010
AGM Information Classification · 98% confidence The document text is structured around an agenda for a 'Hauptversammlung' (General Meeting) dated May 21, 2010, which includes voting items ('Tagesordnungspunkte') such as the approval of the annual financial statements, discharge of board members, and resolutions on capital structure (share acquisition/issuance). It also contains detailed 'Bericht des Vorstands' (Management Report) sections covering operational and financial reviews for 2009 and outlooks for 2010, segmented by business units (Partnered Discovery, Proprietary Development, AbD Serotec). The content is a comprehensive review of the past year's performance and future strategy presented at a shareholder meeting. This strongly indicates materials related to an Annual General Meeting (AGM). Since the document contains the agenda and detailed reports presented at the meeting, the most appropriate classification is AGM Information (AGM-R), rather than the full 10-K or a simple Earnings Release (ER).
2010-05-21 German
BioEquity, Zurich, Switzerland
Investor Presentation Classification · 95% confidence The document text contains a title 'Bio€q y uit Europe 2010' and a date 'Zurich – May 19, 2010'. It includes sections like 'Recent Developments' with dated entries and a detailed table titled 'Current Product Pipeline' which lists drug candidates, partners, targets, phases (Phase 1, Phase 2, Phase 3), and market information. The content is highly structured, focusing on scientific/product development progress and pipeline status, which is characteristic of an Investor Presentation (IP) or a detailed factsheet/supplement. Given the depth of the pipeline table and the strategic overview ('HuCALPLATINUM: Technology p Leadership'), it strongly suggests a presentation designed to inform investors about the company's assets and strategy, rather than a formal regulatory filing (like 10-K or IR) or a brief announcement (like ER or RPA). It is not an AGM-R (no voting/meeting details), not a 10-K (not a full annual report), not an ER (too detailed for just highlights), and not an RPA (it is the content, not an announcement of content). The structure and focus align best with an Investor Presentation (IP).
2010-05-19 English
Q1 Bericht 2010
Interim / Quarterly Report Classification · 100% confidence The document is a 'Zwischenbericht' (Interim Report) for the period January to March 2010 for MorphoSys AG. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow statement, and management discussion and analysis (Konzern-Zwischenlagebericht). Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2010
2010-04-27 German
Q1 Report 2010
Interim / Quarterly Report
2010-04-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.